Immunovia, Inc. is excited to introduce the IMMray® PanCan-d test, a microarray which analyzes 9 biomarkers including CA19-9 to detect pancreatic ductal adenocarcinoma (PDAC) in serum. In a recent peer-reviewed publication by Brand et al, the IMMray PanCan-d test identified Stage I & II PDAC (n=56) vs controls (individuals enrolled in a familial/hereditary pancreatic cancer surveillance program and healthy controls, n=379) with 99% specificity and 89% sensitivity. Across all PDAC stages (n=157) vs controls (n=379), the sensitivity increased to 92% with 99% specificity.
Additional Info
Will your company display a new product or promote a new indication/enhanced feature(s) for an existing product in your booth?
Yes